{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:11:49Z","timestamp":1792707109815,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-11749-3","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:08:35Z","timestamp":1775038115000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Interferon dynamics in deltaretroviruses: why HTLV-1 evades, but BLV responds"],"prefix":"10.1007","volume":"53","author":[{"given":"Mohammad Mehdi","family":"Akbarin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Farjami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1682-8104","authenticated-orcid":false,"given":"Hugo Ram\u00edrez","family":"\u00c1lvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"1","key":"11749_CR1","doi-asserted-by":"publisher","first-page":"e0001484","DOI":"10.1371\/journal.pgph.0001484","volume":"3","author":"M Mahdifar","year":"2023","unstructured":"Mahdifar M, Akbari-Eidgahi MR, Mosavat A, Pourreza A, Akbarin MM, Valizadeh N et al (2023) Immigrating and vicinity are not risk factors in the prevalence and transmission rate of human T-lymphotropic virus type 1: A Survey in an endemic region of Iran and Afghan refugees. PLOS Glob Public Health 3(1):e0001484. https:\/\/doi.org\/10.1371\/journal.pgph.0001484","journal-title":"PLOS Glob Public Health"},{"issue":"8452","key":"11749_CR2","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/s0140-6736(85)92734-5","volume":"2","author":"A Gessain","year":"1985","unstructured":"Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender A et al (1985) Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2(8452):407\u2013410. https:\/\/doi.org\/10.1016\/s0140-6736(85)92734-5","journal-title":"Lancet"},{"issue":"12","key":"11749_CR3","doi-asserted-by":"publisher","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","volume":"77","author":"BJ Poiesz","year":"1980","unstructured":"Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC (1980) Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 77(12):7415\u20137419. https:\/\/doi.org\/10.1073\/pnas.77.12.7415","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"11749_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","volume":"50","author":"T Uchiyama","year":"1977","unstructured":"Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H (1977) Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50(3):481\u2013492","journal-title":"Blood"},{"issue":"5","key":"11749_CR5","doi-asserted-by":"publisher","first-page":"294","DOI":"10.30476\/IJMS.2023.97867.2973","volume":"49","author":"M Davoudi","year":"2024","unstructured":"Davoudi M, Boostani R, Manzari ZS (2024) Lived Experience of Human T-cell Leukemia Virus type-1 -Associated Myelopathy\/Tropical Spastic Paraparesis (HAM\/TSP): A Phenomenology Study. Iran J Med Sci 49(5):294\u2013301. https:\/\/doi.org\/10.30476\/IJMS.2023.97867.2973","journal-title":"Iran J Med Sci"},{"key":"11749_CR6","doi-asserted-by":"publisher","first-page":"122973","DOI":"10.1016\/j.jns.2024.122973","volume":"459","author":"L Saab","year":"2024","unstructured":"Saab L, DiCapua D, Zubair AS (2024) HTLV-1 associated myelopathy\/tropical spastic paraparesis (HAM\/TSP): Case based discussion of risk factors, clinical, and therapeutic considerations. J Neurol Sci 459:122973. https:\/\/doi.org\/10.1016\/j.jns.2024.122973","journal-title":"J Neurol Sci"},{"key":"11749_CR7","doi-asserted-by":"publisher","first-page":"107635","DOI":"10.1016\/j.leukres.2024.107635","volume":"148","author":"DA Weterings","year":"2025","unstructured":"Weterings DA, Rowan AG, Cook LB (2025) Immunological aspects of HTLV-1 persistence; for the prevention and treatment of Adult T-cell leukaemia-lymphoma (ATL). Leuk Res 148:107635. https:\/\/doi.org\/10.1016\/j.leukres.2024.107635","journal-title":"Leuk Res"},{"issue":"1","key":"11749_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12977-024-00653-y","volume":"21","author":"F Saeedi-Moghaddam","year":"2024","unstructured":"Saeedi-Moghaddam F, Mohammaditabar M, Mozhgani SH (2024) Bovine leukemia virus (BLV) and risk of breast cancer; a systematic review and meta-analysis. Retrovirology 21(1):20. https:\/\/doi.org\/10.1186\/s12977-024-00653-y","journal-title":"Retrovirology"},{"issue":"1","key":"11749_CR9","doi-asserted-by":"publisher","first-page":"18659","DOI":"10.1038\/s41598-023-45981-9","volume":"13","author":"D Pichardo-Matamoros","year":"2023","unstructured":"Pichardo-Matamoros D, Sevilla F, Elizondo-Salazar J, Jimenez-Sanchez C, Roldan ERS, Soler C et al (2023) Exploration of semen quality analyzed by casa-mot systems of brahman bulls infected with BLV and BHV-1. Sci Rep 13(1):18659. https:\/\/doi.org\/10.1038\/s41598-023-45981-9","journal-title":"Sci Rep"},{"issue":"1","key":"11749_CR10","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13567-019-0724-1","volume":"50","author":"S Watanuki","year":"2019","unstructured":"Watanuki S, Takeshima SN, Borjigin L, Sato H, Bai L, Murakami H et al (2019) Visualizing bovine leukemia virus (BLV)-infected cells and measuring BLV proviral loads in the milk of BLV seropositive dams. Vet Res 50(1):102. https:\/\/doi.org\/10.1186\/s13567-019-0724-1","journal-title":"Vet Res"},{"issue":"5","key":"11749_CR11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3201\/eid2005.131298","volume":"20","author":"GC Buehring","year":"2014","unstructured":"Buehring GC, Shen HM, Jensen HM, Choi KY, Sun D, Nuovo G (2014) Bovine leukemia virus DNA in human breast tissue. Emerg Infect Dis 20(5):772\u2013782. https:\/\/doi.org\/10.3201\/eid2005.131298","journal-title":"Emerg Infect Dis"},{"issue":"1","key":"11749_CR12","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.1038\/s41598-022-08181-5","volume":"12","author":"Z Khan","year":"2022","unstructured":"Khan Z, Abubakar M, Arshed MJ, Aslam R, Sattar S, Shah NA et al (2022) Molecular investigation of possible relationships concerning bovine leukemia virus and breast cancer. Sci Rep 12(1):4161. https:\/\/doi.org\/10.1038\/s41598-022-08181-5","journal-title":"Sci Rep"},{"key":"11749_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13027-020-00314-7","volume":"15","author":"A Khatami","year":"2020","unstructured":"Khatami A, Pormohammad A, Farzi R, Saadati H, Mehrabi M, Kiani SJ et al (2020) Bovine Leukemia virus (BLV) and risk of breast cancer: a systematic review and meta-analysis of case-control studies. Infect Agent Cancer 15:48. https:\/\/doi.org\/10.1186\/s13027-020-00314-7","journal-title":"Infect Agent Cancer"},{"key":"11749_CR14","doi-asserted-by":"publisher","first-page":"1720247","DOI":"10.3389\/fcimb.2025.1720247","volume":"15","author":"C Yu","year":"2025","unstructured":"Yu C, Li Y, Wang H, Jiang F, Xu C, Li N et al (2025) Bovine leukemia virus: an emerging concern for zoonotic cross-species transmission. Front Cell Infect Microbiol 15:1720247. https:\/\/doi.org\/10.3389\/fcimb.2025.1720247","journal-title":"Front Cell Infect Microbiol"},{"key":"11749_CR15","doi-asserted-by":"publisher","unstructured":"Di Marco L, Cannova S, Ferrigno E, Landro G, Nonni R, Mantia C et al (2025) A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs). Viruses 17(2). https:\/\/doi.org\/10.3390\/v17020163","DOI":"10.3390\/v17020163"},{"key":"11749_CR16","doi-asserted-by":"publisher","unstructured":"Harding AT, Zhang Y, Chen JJ, Antonucci JM, Richards A, Leger V et al (2025) Oxidative Stress and Interferon Signaling Drive Differential Pathogenesis of Ancestral and Contemporary Zika Viruses in Human Cerebral Organoids. bioRxiv. https:\/\/doi.org\/10.1101\/2025.08.12.669648","DOI":"10.1101\/2025.08.12.669648"},{"issue":"1","key":"11749_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.50.1","volume":"50","author":"Y Satou","year":"2010","unstructured":"Satou Y, Matsuoka M (2010) HTLV-1 and the host immune system: how the virus disrupts immune regulation, leading to HTLV-1 associated diseases. J Clin experimental hematopathology: JCEH 50(1):1\u20138. https:\/\/doi.org\/10.3960\/jslrt.50.1","journal-title":"J Clin experimental hematopathology: JCEH"},{"issue":"1","key":"11749_CR18","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12977-019-0488-8","volume":"16","author":"A Abdala","year":"2019","unstructured":"Abdala A, Alvarez I, Brossel H, Calvinho L, Carignano H, Franco L et al (2019) BLV: lessons on vaccine development. Retrovirology 16(1):26. https:\/\/doi.org\/10.1186\/s12977-019-0488-8","journal-title":"Retrovirology"},{"key":"11749_CR19","doi-asserted-by":"crossref","unstructured":"Fernandez-Ruiz R, Niewold T (2021) Chapter 21 - The role of interferons in systemic lupus erythematosus. In: Tsokos GC, editor. Systemic Lupus Erythematosus (Second Edition). Academic Press; pp. 171-8","DOI":"10.1016\/B978-0-12-814551-7.00021-0"},{"issue":"5164","key":"11749_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"JE Darnell Jr","year":"1994","unstructured":"Darnell JE Jr., Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264(5164):1415\u20131421. https:\/\/doi.org\/10.1126\/science.8197455","journal-title":"Science"},{"key":"11749_CR21","doi-asserted-by":"publisher","first-page":"1284056","DOI":"10.3389\/fimmu.2024.1284056","volume":"15","author":"E Clayton","year":"2024","unstructured":"Clayton E, Atasoy MO, Naggar RFE, Franco AC, Rohaim MA, Munir M (2024) Interferon-induced protein with tetratricopeptide repeats 5 of black fruit bat (Pteropus alecto) displays a broad inhibition of RNA viruses. Front Immunol 15:1284056. https:\/\/doi.org\/10.3389\/fimmu.2024.1284056","journal-title":"Front Immunol"},{"key":"11749_CR22","doi-asserted-by":"publisher","first-page":"110619","DOI":"10.1016\/j.fsi.2025.110619","volume":"166","author":"L Li","year":"2025","unstructured":"Li L, Cai J, Wu Z, Yuan Q, Xia H, Lu Y et al (2025) Tilapia IFP35 is differently induced by three subgroups of type I IFNs via the JAK-STAT signaling. Fish Shellfish Immunol 166:110619. https:\/\/doi.org\/10.1016\/j.fsi.2025.110619","journal-title":"Fish Shellfish Immunol"},{"issue":"6","key":"11749_CR23","doi-asserted-by":"publisher","first-page":"103334","DOI":"10.1016\/j.autrev.2023.103334","volume":"22","author":"M Gasparotto","year":"2023","unstructured":"Gasparotto M, Franco C, Zanatta E, Ghirardello A, Zen M, Iaccarino L et al (2023) The interferon in idiopathic inflammatory myopathies: Different signatures and new therapeutic perspectives. A literature review. Autoimmun Rev 22(6):103334. https:\/\/doi.org\/10.1016\/j.autrev.2023.103334","journal-title":"Autoimmun Rev"},{"issue":"2","key":"11749_CR24","doi-asserted-by":"publisher","first-page":"e0149423","DOI":"10.1128\/jvi.01494-23","volume":"98","author":"T Rowe","year":"2024","unstructured":"Rowe T, Davis W, Wentworth DE, Ross T (2024) Differential interferon responses to influenza A and B viruses in primary ferret respiratory epithelial cells. J Virol 98(2):e0149423. https:\/\/doi.org\/10.1128\/jvi.01494-23","journal-title":"J Virol"},{"issue":"2","key":"11749_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nri3787","volume":"15","author":"F McNab","year":"2015","unstructured":"McNab F, Mayer-Barber K, Sher A, Wack A, O\u2019Garra A (2015) Type I interferons in infectious disease. Nat Rev Immunol 15(2):87\u2013103. https:\/\/doi.org\/10.1038\/nri3787","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"11749_CR26","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1089\/jir.2005.25.694","volume":"25","author":"C Manca","year":"2005","unstructured":"Manca C, Tsenova L, Freeman S, Barczak AK, Tovey M, Murray PJ et al (2005) Hypervirulent M. tuberculosis W\/Beijing strains upregulate type I IFNs and increase expression of negative regulators of the Jak-Stat pathway. J Interferon Cytokine Res 25(11):694\u2013701. https:\/\/doi.org\/10.1089\/jir.2005.25.694","journal-title":"J Interferon Cytokine Res"},{"issue":"6693","key":"11749_CR27","doi-asserted-by":"publisher","first-page":"eadl2016","DOI":"10.1126\/science.adl2016","volume":"384","author":"J-L Casanova","year":"2024","unstructured":"Casanova J-L, MacMicking JD, Nathan CF (2024) Interferon-\u03b3 and infectious diseases: Lessons and prospects. Science 384(6693):eadl2016. https:\/\/doi.org\/10.1126\/science.adl2016","journal-title":"Science"},{"key":"11749_CR28","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Bielma MF, Falf\u00e1n-Valencia R, Abarca-Rojano E, P\u00e9rez-Rubio G (2023) Participation of Single-Nucleotide Variants in IFNAR1 and IFNAR2 in the Immune Response against SARS-CoV-2 Infection: A Systematic Review. Pathogens 12(11). https:\/\/doi.org\/10.3390\/pathogens12111320","DOI":"10.3390\/pathogens12111320"},{"issue":"7","key":"11749_CR29","doi-asserted-by":"publisher","first-page":"e487","DOI":"10.1016\/S2666-5247(23)00095-2","volume":"4","author":"M Yaugel-Novoa","year":"2023","unstructured":"Yaugel-Novoa M, Bourlet T, Longet S, Botelho-Nevers E, Paul S (2023) Association of IFNAR1 and IFNAR2 with COVID-19 severity. Lancet Microbe 4(7):e487. https:\/\/doi.org\/10.1016\/S2666-5247(23)00095-2","journal-title":"Lancet Microbe"},{"issue":"7","key":"11749_CR30","doi-asserted-by":"publisher","first-page":"e0306429","DOI":"10.1371\/journal.pone.0306429","volume":"19","author":"A Serafino","year":"2024","unstructured":"Serafino A, Bertinat YA, Bueno J, Pittaluga JR, Birnberg Weiss F, Milillo MA et al (2024) Beyond its preferential niche: Brucella abortus RNA down-modulates the IFN-gamma-induced MHC-I expression in epithelial and endothelial cells. PLoS ONE 19(7):e0306429. https:\/\/doi.org\/10.1371\/journal.pone.0306429","journal-title":"PLoS ONE"},{"issue":"1","key":"11749_CR31","doi-asserted-by":"publisher","first-page":"2523621","DOI":"10.1080\/15384047.2025.2523621","volume":"26","author":"MZ Zhao","year":"2025","unstructured":"Zhao MZ, Zheng HC, Sun Y, Jiang XF, Liu L, Dang CY et al (2025) IFN-gamma downregulates miR-4319 to enhance NLRC5 and MHC-I expression in MHC-I-deficient breast cancer cells. Cancer Biol Ther 26(1):2523621. https:\/\/doi.org\/10.1080\/15384047.2025.2523621","journal-title":"Cancer Biol Ther"},{"key":"11749_CR32","doi-asserted-by":"publisher","unstructured":"McCarthy MW (2023) Interferon lambda as a potential treatment for COVID-19. Expert opinion on biological therapy. 23(5):389\u2013394. https:\/\/doi.org\/10.1080\/14712598.2023.2211709","DOI":"10.1080\/14712598.2023.2211709"},{"key":"11749_CR33","doi-asserted-by":"publisher","first-page":"104614","DOI":"10.1016\/j.critrevonc.2025.104614","volume":"207","author":"B Ahmed","year":"2025","unstructured":"Ahmed B, Aliyu M, Getso MI, Bala JA, Ahmed RJ, Kabuga AI et al (2025) Exploring the impact of interferon-gamma single nucleotide polymorphisms on HTLV-1 infection: Unraveling genetic influences in viral pathogenesis. Crit Rev Oncol Hematol 207:104614. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104614","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"11749_CR34","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/intimm\/dxp074","volume":"21","author":"N Takatsuka","year":"2009","unstructured":"Takatsuka N, Hasegawa A, Takamori A, Shimizu Y, Kato H, Ohashi T et al (2009) Induction of IL-10- and IFN-gamma-producing T-cell responses by autoreactive T-cells expressing human T-cell leukemia virus type I Tax. Int Immunol 21(9):1089\u20131100. https:\/\/doi.org\/10.1093\/intimm\/dxp074","journal-title":"Int Immunol"},{"issue":"1","key":"11749_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1292\/jvms.69.15","volume":"69","author":"J Kohara","year":"2007","unstructured":"Kohara J, Yokomizo Y (2007) In vitro and in vivo effects of recombinant bovine interferon-tau on bovine leukemia virus. J Vet Med Sci 69(1):15\u201319. https:\/\/doi.org\/10.1292\/jvms.69.15","journal-title":"J Vet Med Sci"},{"issue":"2","key":"11749_CR36","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1515\/acve-2015-0024","volume":"65","author":"K Sei-Ichi","year":"2015","unstructured":"Sei-Ichi K, Tomohiro I, Kei-Ichi M, Satoru K, Yosuke M, Hiromichi O, Cellular, immune response to interferon-\u03c4 in peripheral blood mononuclear cells of Japanese black cattle with bovine leukemia virus infection (2015) Acta Vet-Beograd 65(2):287\u2013296. https:\/\/doi.org\/10.1515\/acve-2015-0024","journal-title":"Acta Vet-Beograd"},{"issue":"3\u20134","key":"11749_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0165-2427(97)00083-4","volume":"59","author":"RG Keefe","year":"1997","unstructured":"Keefe RG, Ferrick DA, Stott JL (1997) Cytokine transcription in lymph nodes of cattle in different stages of bovine leukemia virus infection. Vet Immunol Immunop 59(3\u20134):271\u2013283. https:\/\/doi.org\/10.1016\/S0165-2427(97)00083","journal-title":"Vet Immunol Immunop"},{"issue":"3","key":"11749_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0147-9571(99)00074-0","volume":"23","author":"B Yakobson","year":"2000","unstructured":"Yakobson B, Brenner J, Ungar-Waron H, Trainin Z (2000) Cellular immune response cytokine expression during the initial stage of bovine leukemia virus (BLV) infection determines the disease progression to persistent lymphocytosis. Comp Immunol Microb 23(3):197\u2013208 doi: Doi 10.1016\/S0147-9571(99)00074\u2009\u2013\u20090","journal-title":"Comp Immunol Microb"},{"issue":"7","key":"11749_CR39","doi-asserted-by":"publisher","first-page":"5526","DOI":"10.1128\/JVI.72.7.5526-5534.1998","volume":"72","author":"V Kiermer","year":"1998","unstructured":"Kiermer V, Van Lint C, Briclet D, Vanhulle C, Kettmann R, Verdin E et al (1998) An interferon regulatory factor binding site in the U5 region of the bovine leukemia virus long terminal repeat stimulates Tax-independent gene expression. J Virol 72(7):5526\u20135534. https:\/\/doi.org\/10.1128\/JVI.72.7.5526-5534.1998","journal-title":"J Virol"},{"issue":"1\u20132","key":"11749_CR40","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.vetimm.2006.09.011","volume":"115","author":"T Usui","year":"2007","unstructured":"Usui T, Konnai S, Ohashi K, Onuma M (2007) Interferon-gamma expression associated with suppression of bovine leukemia virus at the early phase of infection in sheep. Vet Immunol Immunopathol 115(1\u20132):17\u201323. https:\/\/doi.org\/10.1016\/j.vetimm.2006.09.011","journal-title":"Vet Immunol Immunopathol"},{"key":"11749_CR41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.rvsc.2016.06.016","volume":"107","author":"MVN Farias","year":"2016","unstructured":"Farias MVN, Lendez PA, Marin M, Quintana S, Martinez-Cuesta L, Ceriani MC et al (2016) Toll-like receptors, IFN-gamma and IL-12 expression in bovine leukemia virus-infected animals with low or high proviral load. Res Vet Sci 107:190\u2013195. https:\/\/doi.org\/10.1016\/j.rvsc.2016.06.016","journal-title":"Res Vet Sci"},{"issue":"4","key":"11749_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4149\/av_2020_409","volume":"64","author":"C Usuga-Monroy","year":"2020","unstructured":"Usuga-Monroy C, Herrera LGG, Zuluaga JJE, D\u00edaz FJ, L\u00f3pez-Herrera A (2020) IFN-\u03b3 mRNA expression is lower in Holstein cows infected with bovine leukemia virus with high proviral load and persistent lymphocytosis. Acta Virol 64(4):451\u2013456. https:\/\/doi.org\/10.4149\/av_2020_409","journal-title":"Acta Virol"},{"issue":"4","key":"11749_CR43","first-page":"269","volume":"86","author":"E Marin-Flamand","year":"2022","unstructured":"Marin-Flamand E, Araiza-Hernandez DM, Vargas-Ruiz A, Rangel-Rodriguez IC, Gonzalez-Tapia LA, Ramirez-Alvarez H et al (2022) Relationship of persistent lymphocytosis, antibody titers, and proviral load with expression of interleukin-12, interferon-gamma, interleukin-2, interleukin-4, interleukin-10, and transforming growth factor-beta in cows infected with bovine leukemia virus from a high-prevalence dairy complex. Can J Vet Res 86(4):269\u2013285","journal-title":"Can J Vet Res"},{"issue":"8","key":"11749_CR44","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.14202\/vetworld.2024.1672-1679","volume":"17","author":"S Borovikov","year":"2024","unstructured":"Borovikov S, Tursunov K, Adish Z, Tokhtarova L, Mukantayev K (2024) Effects of combined cytotoxic T-lymphocyte antigen 4 and programed death 1 ligand-receptor blockade on interferon-gamma production in bovine leukemia virus-infected cattle. Vet World 17(8):1672\u20131679. https:\/\/doi.org\/10.14202\/vetworld.2024.1672-1679","journal-title":"Vet World"},{"issue":"4","key":"11749_CR45","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4149\/av_2020_409","volume":"64","author":"C Usuga-Monroy","year":"2020","unstructured":"Usuga-Monroy C, Gonzalez Herrera LG, Echeverri Zuluaga JJ, Diaz FJ, Lopez-Herrera A (2020) IFN-gamma mRNA expression is lower in Holstein cows infected with bovine leukemia virus with high proviral load and persistent lymphocytosis. Acta Virol 64(4):451\u2013456. https:\/\/doi.org\/10.4149\/av_2020_409","journal-title":"Acta Virol"},{"issue":"11","key":"11749_CR46","doi-asserted-by":"publisher","first-page":"e1001177","DOI":"10.1371\/journal.ppat.1001177","volume":"6","author":"S Oliere","year":"2010","unstructured":"Oliere S, Hernandez E, Lezin A, Arguello M, Douville R, Nguyen TL et al (2010) HTLV-1 evades type I interferon antiviral signaling by inducing the suppressor of cytokine signaling 1 (SOCS1). PLoS Pathog 6(11):e1001177. https:\/\/doi.org\/10.1371\/journal.ppat.1001177","journal-title":"PLoS Pathog"},{"key":"11749_CR47","doi-asserted-by":"publisher","unstructured":"Iuliano M, Mangino G, Chiantore MV, Di Bonito P, Rosa P, Affabris E et al (2021) Virus-induced tumorigenesis and IFN system. Biology (Basel) 10(10). https:\/\/doi.org\/10.3390\/biology10100994","DOI":"10.3390\/biology10100994"},{"issue":"6","key":"11749_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1177\/095632020401500601","volume":"15","author":"MJ Grace","year":"2004","unstructured":"Grace MJ, Cutler D (2004) Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK\/STAT pathway. Antivir Chem Chemother 15(6):287\u2013297. https:\/\/doi.org\/10.1177\/095632020401500601","journal-title":"Antivir Chem Chemother"},{"issue":"10","key":"11749_CR49","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1182\/blood-2004-01-0266","volume":"104","author":"S Mitra-Kaushik","year":"2004","unstructured":"Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L (2004) Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood 104(10):3305\u20133311. https:\/\/doi.org\/10.1182\/blood-2004-01-0266","journal-title":"Blood"},{"issue":"7","key":"11749_CR50","doi-asserted-by":"publisher","first-page":"e1729","DOI":"10.1371\/journal.pntd.0001729","volume":"6","author":"B Moens","year":"2012","unstructured":"Moens B, Decanine D, Menezes SM, Khouri R, Silva-Santos G, Lopez G et al (2012) Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-alpha in HTLV-1-associated myelopathy. PLoS Negl Trop Dis 6(7):e1729. https:\/\/doi.org\/10.1371\/journal.pntd.0001729","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"11749_CR51","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1046\/j.1365-2249.2002.01733.x","volume":"127","author":"M Satoh","year":"2002","unstructured":"Satoh M, Toma H, Sato Y, Takara M, Shiroma Y, Kiyuna S et al (2002) Reduced efficacy of treatment of strongyloidiasis in HTLV-I carriers related to enhanced expression of IFN-gamma and TGF-beta1. Clin Exp Immunol 127(2):354\u2013359. https:\/\/doi.org\/10.1046\/j.1365-2249.2002.01733.x","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"11749_CR52","doi-asserted-by":"publisher","first-page":"e1006494","DOI":"10.1371\/journal.ppat.1006494","volume":"13","author":"G Rizkallah","year":"2017","unstructured":"Rizkallah G, Alais S, Futsch N, Tanaka Y, Journo C, Mahieux R et al (2017) Correction: Dendritic cell maturation, but not type I interferon exposure, restricts infection by HTLV-1, and viral transmission to T-cells. PLoS Pathog 13(7):e1006494. https:\/\/doi.org\/10.1371\/journal.ppat.1006494","journal-title":"PLoS Pathog"},{"issue":"4","key":"11749_CR53","doi-asserted-by":"publisher","first-page":"4753","DOI":"10.3892\/ol.2018.8014","volume":"15","author":"A Refaat","year":"2018","unstructured":"Refaat A, Owis M, Abdelhamed S, Saiki I, Sakurai H (2018) Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model. Oncol Lett 15(4):4753\u20134758. https:\/\/doi.org\/10.3892\/ol.2018.8014","journal-title":"Oncol Lett"},{"key":"11749_CR54","doi-asserted-by":"publisher","first-page":"1239706","DOI":"10.3389\/fmed.2023.1239706","volume":"10","author":"NR Machado","year":"2023","unstructured":"Machado NR, Fagundes BO, Fernandes LA, de Oliveira ACP, Nukui Y, Casseb J et al (2023) Differential modulation of IL-4, IL-10, IL-17, and IFN-gamma production mediated by IgG from Human T-lymphotropic virus-1 (HTLV-1) infected patients on healthy peripheral T (CD4+, CD8+, and gammadelta) and B cells. Front Med (Lausanne) 10:1239706. https:\/\/doi.org\/10.3389\/fmed.2023.1239706","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"11749_CR55","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1006\/viro.1999.9679","volume":"257","author":"D Smith","year":"1999","unstructured":"Smith D, Buckle GJ, Hafler DA, Frank DA, Hollsberg P (1999) HTLV-I-infected T cells evade the antiproliferative action of IFN-beta. Virology 257(2):314\u2013321. https:\/\/doi.org\/10.1006\/viro.1999.9679","journal-title":"Virology"},{"issue":"10","key":"11749_CR56","doi-asserted-by":"publisher","first-page":"e1005214","DOI":"10.1371\/journal.ppat.1005214","volume":"11","author":"Y Mitagami","year":"2015","unstructured":"Mitagami Y, Yasunaga J, Kinosada H, Ohshima K, Matsuoka M (2015) Correction: Interferon-gamma Promotes Inflammation and Development of T-Cell Lymphoma in HTLV-1 bZIP Factor Transgenic Mice. PLoS Pathog 11(10):e1005214. https:\/\/doi.org\/10.1371\/journal.ppat.1005214","journal-title":"PLoS Pathog"},{"key":"11749_CR57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.virol.2014.12.005","volume":"476","author":"E Diani","year":"2015","unstructured":"Diani E, Avesani F, Bergamo E, Cremonese G, Bertazzoni U, Romanelli MG (2015) HTLV-1 Tax protein recruitment into IKKepsilon and TBK1 kinase complexes enhances IFN-I expression. Virology 476:92\u201399. https:\/\/doi.org\/10.1016\/j.virol.2014.12.005","journal-title":"Virology"},{"issue":"1","key":"11749_CR58","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1348-0421.1997.tb01173.x","volume":"41","author":"N Yokosawa","year":"1997","unstructured":"Yokosawa N, Indoh T, Kubota T, Yashiki T, Fujii N (1997) Suppressed induction of 2-5AS in cells with HTLV-I is not associated with the fluctuation of IFN-receptor, IFN-regulatory factors (IRF-1 and IRF-2) or STAT-1 alpha. Microbiol Immunol 41(1):63\u201366. https:\/\/doi.org\/10.1111\/j.1348-0421.1997.tb01173.x","journal-title":"Microbiol Immunol"},{"issue":"2","key":"11749_CR59","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2011.05.014","volume":"409","author":"R Mukai","year":"2011","unstructured":"Mukai R, Ohshima T (2011) Dual effects of HTLV-1 bZIP factor in suppression of interferon regulatory factor 1. Biochem Biophys Res Commun 409(2):328\u2013332. https:\/\/doi.org\/10.1016\/j.bbrc.2011.05.014","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"11749_CR60","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1089\/08892220050193047","volume":"16","author":"S Sharma","year":"2000","unstructured":"Sharma S, Mamane Y, Grandvaux N, Bartlett J, Petropoulos L, Lin R et al (2000) Activation and regulation of interferon regulatory factor 4 in HTLV type 1-infected T lymphocytes. AIDS Res Hum Retroviruses 16(16):1613\u20131622. https:\/\/doi.org\/10.1089\/08892220050193047","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"11","key":"11749_CR61","doi-asserted-by":"publisher","first-page":"5667","DOI":"10.4049\/jimmunol.168.11.5667","volume":"168","author":"JM Mariner","year":"2002","unstructured":"Mariner JM, Mamane Y, Hiscott J, Waldmann TA, Azimi N (2002) IFN regulatory factor 4 participates in the human T cell lymphotropic virus type I-mediated activation of the IL-15 receptor alpha promoter. J Immunol 168(11):5667\u20135674. https:\/\/doi.org\/10.4049\/jimmunol.168.11.5667","journal-title":"J Immunol"},{"issue":"6","key":"11749_CR62","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.4049\/jimmunol.169.6.3120","volume":"169","author":"S Sharma","year":"2002","unstructured":"Sharma S, Grandvaux N, Mamane Y, Genin P, Azimi N, Waldmann T et al (2002) Regulation of IFN regulatory factor 4 expression in human T cell leukemia virus-I-transformed T cells. J Immunol 169(6):3120\u20133130. https:\/\/doi.org\/10.4049\/jimmunol.169.6.3120","journal-title":"J Immunol"},{"issue":"5","key":"11749_CR63","doi-asserted-by":"publisher","first-page":"e1426423","DOI":"10.1080\/2162402X.2018.1426423","volume":"7","author":"R Khouri","year":"2018","unstructured":"Khouri R, Silva-Santos G, Dierckx T, Menezes SM, Decanine D, Theys K et al (2018) A genetic IFN\/STAT1\/FAS axis determines CD4 T stem cell memory levels and apoptosis in healthy controls and Adult T-cell Leukemia patients. Oncoimmunology 7(5):e1426423. https:\/\/doi.org\/10.1080\/2162402X.2018.1426423","journal-title":"Oncoimmunology"},{"key":"11749_CR64","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3389\/fcimb.2020.00246","volume":"10","author":"MAF Queiroz","year":"2020","unstructured":"Queiroz MAF, Amoras E, Moura TCF, da Costa CA, de Sousa MS, Lima SS et al (2020) The SAMHD1 rs6029941 (A\/G) Polymorphism Seems to Influence the HTLV-1 Proviral Load and IFN-Alpha Levels. Front Cell Infect Microbiol 10:246. https:\/\/doi.org\/10.3389\/fcimb.2020.00246","journal-title":"Front Cell Infect Microbiol"},{"key":"11749_CR65","doi-asserted-by":"publisher","first-page":"1462352","DOI":"10.3389\/fimmu.2024.1462352","volume":"15","author":"EGM Santana","year":"2024","unstructured":"Santana EGM, Ferreira FDS, Brito W, Lopes FT, de Lima ACR, Neto G et al (2024) TLR7 rs179008 (A\/T) and TLR7 rs3853839 (C\/G) polymorphisms are associated with variations in IFN-alpha levels in HTLV-1 infection. Front Immunol 15:1462352. https:\/\/doi.org\/10.3389\/fimmu.2024.1462352","journal-title":"Front Immunol"},{"key":"11749_CR66","doi-asserted-by":"publisher","first-page":"1604259","DOI":"10.3389\/fcimb.2025.1604259","volume":"15","author":"FDS Ferreira","year":"2025","unstructured":"Ferreira FDS, Brito W, Santana EGM, Oliveira AKA, de Lima ACR, Amoras E et al (2025) TLR3 rs3775291 C\/T polymorphism is associated with elevated IFN-alpha level in asymptomatic HTLV-1 infection. Front Cell Infect Microbiol 15:1604259. https:\/\/doi.org\/10.3389\/fcimb.2025.1604259","journal-title":"Front Cell Infect Microbiol"},{"key":"11749_CR67","doi-asserted-by":"publisher","unstructured":"Cuenca N, Cordero D, Lopez-Ulloa B, Association Between (2025) IL-28B (rs8099917) and IL-28B (rs12979860) with predisposition to diseases related to the HTLV-1: systematic review and meta-analysis. Pathogens 14(5). https:\/\/doi.org\/10.3390\/pathogens14050470","DOI":"10.3390\/pathogens14050470"},{"issue":"2","key":"11749_CR68","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0165-5728(89)90037-4","volume":"23","author":"S Ijichi","year":"1989","unstructured":"Ijichi S, Eiraku N, Osame M, Izumo S, Kubota R, Maruyama I et al (1989) In vitro modulation of lymphocyte proliferation by prednisolone and interferon-alpha in patients with HTLV-I-associated myelopathy (HAM). J Neuroimmunol 23(2):175\u2013178. https:\/\/doi.org\/10.1016\/0165-5728(89)90037-4","journal-title":"J Neuroimmunol"},{"issue":"1","key":"11749_CR69","doi-asserted-by":"publisher","first-page":"e1002480","DOI":"10.1371\/journal.ppat.1002480","volume":"8","author":"S Tattermusch","year":"2012","unstructured":"Tattermusch S, Skinner JA, Chaussabel D, Banchereau J, Berry MP, McNab FW et al (2012) Systems biology approaches reveal a specific interferon-inducible signature in HTLV-1 associated myelopathy. PLoS Pathog 8(1):e1002480. https:\/\/doi.org\/10.1371\/journal.ppat.1002480","journal-title":"PLoS Pathog"},{"issue":"2","key":"11749_CR70","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0165-5728(93)90014-p","volume":"42","author":"Y Kuroda","year":"1993","unstructured":"Kuroda Y, Matsui M (1993) Cerebrospinal fluid interferon-gamma is increased in HTLV-I-associated myelopathy. J Neuroimmunol 42(2):223\u2013226. https:\/\/doi.org\/10.1016\/0165-5728(93)90014-p","journal-title":"J Neuroimmunol"},{"issue":"2","key":"11749_CR71","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/s0165-5728(99)00175-7","volume":"102","author":"R Kubota","year":"2000","unstructured":"Kubota R, Kawanishi T, Matsubara H, Manns A, Jacobson S (2000) HTLV-I specific IFN-gamma+ CD8\u2009+\u2009lymphocytes correlate with the proviral load in peripheral blood of infected individuals. J Neuroimmunol 102(2):208\u2013215. https:\/\/doi.org\/10.1016\/s0165-5728(99)00175-7","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"11749_CR72","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jneuroim.2004.10.007","volume":"159","author":"N Fukushima","year":"2005","unstructured":"Fukushima N, Nishiura Y, Nakamura T, Yamada Y, Kohno S, Eguchi K (2005) Involvement of p38 MAPK signaling pathway in IFN-gamma and HTLV-I expression in patients with HTLV-I-associated myelopathy\/tropical spastic paraparesis. J Neuroimmunol 159(1\u20132):196\u2013202. https:\/\/doi.org\/10.1016\/j.jneuroim.2004.10.007","journal-title":"J Neuroimmunol"},{"issue":"7","key":"11749_CR73","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2169\/internalmedicine.46.6118","volume":"46","author":"N Fukushima","year":"2007","unstructured":"Fukushima N, Nishiura Y, Nakamura T, Kohno S, Eguchi K (2007) Blockade of IL-2 receptor suppresses HTLV-I and IFN-gamma expression in patients with HTLV-I-associated myelopathy\/tropical spastic paraparesis. Intern Med 46(7):347\u2013351. https:\/\/doi.org\/10.2169\/internalmedicine.46.6118","journal-title":"Intern Med"},{"issue":"3","key":"11749_CR74","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s13365-020-00832-5","volume":"26","author":"HR Bidkhori","year":"2020","unstructured":"Bidkhori HR, Hedayati-Moghaddam MR, Mosavat A, Valizadeh N, Tadayon M, Ahmadi Ghezeldasht S et al (2020) The IL-18, IL-12, and IFN-gamma expression in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) patients, HTLV-1 carriers, and healthy subjects. J Neurovirol 26(3):338\u2013346. https:\/\/doi.org\/10.1007\/s13365-020-00832-5","journal-title":"J Neurovirol"},{"issue":"8","key":"11749_CR75","doi-asserted-by":"publisher","first-page":"e6517","DOI":"10.1371\/journal.pone.0006517","volume":"4","author":"Y Yamano","year":"2009","unstructured":"Yamano Y, Araya N, Sato T, Utsunomiya A, Azakami K, Hasegawa D et al (2009) Abnormally high levels of virus-infected IFN-gamma+ CCR4\u2009+\u2009CD4+ CD25\u2009+\u2009T cells in a retrovirus-associated neuroinflammatory disorder. PLoS ONE 4(8):e6517. https:\/\/doi.org\/10.1371\/journal.pone.0006517","journal-title":"PLoS ONE"},{"issue":"2","key":"11749_CR76","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000371766","volume":"58","author":"OM Espindola","year":"2015","unstructured":"Espindola OM, Oliveira LC, Ferreira PM, Leite AC, Lima MA, Andrada-Serpa MJ (2015) High IFN-gamma\/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy\/tropical spastic paraparesis development. Intervirology 58(2):106\u2013114. https:\/\/doi.org\/10.1159\/000371766","journal-title":"Intervirology"},{"issue":"11","key":"11749_CR77","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1089\/AID.2016.0296","volume":"33","author":"H Neco","year":"2017","unstructured":"Neco H, Teixeira V, da Trindade ACL, Magalhaes PMR, de Lorena VMB, Castellano LRC et al (2017) Mediators Go Together: High Production of CXCL9, CXCL10, IFN-gamma, and TNF-alpha in HTLV-1-Associated Myelopathy\/Tropical Spastic Paraparesis. AIDS Res Hum Retroviruses 33(11):1134\u20131139. https:\/\/doi.org\/10.1089\/AID.2016.0296","journal-title":"AIDS Res Hum Retroviruses"},{"key":"11749_CR78","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fmicb.2018.00985","volume":"9","author":"FE Leal","year":"2018","unstructured":"Leal FE, Menezes SM, Costa EAS, Brailey PM, Gama L, Segurado AC et al (2018) Comprehensive Antiretroviral Restriction Factor Profiling Reveals the Evolutionary Imprint of the ex Vivo and in Vivo IFN-beta Response in HTLV-1-Associated Neuroinflammation. Front Microbiol 9:985. https:\/\/doi.org\/10.3389\/fmicb.2018.00985","journal-title":"Front Microbiol"},{"issue":"6","key":"11749_CR79","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/jmv.24721","volume":"89","author":"SH Mozhgani","year":"2017","unstructured":"Mozhgani SH, Jaberi N, Rezaee SA, Bustani R, Jazayeri SM, Akbarin MM et al (2017) Evaluation of HTLV-1 HBZ and proviral load, together with host IFN lambda3, in pathogenesis of HAM\/TSP. J Med Virol 89(6):1102\u20131107. https:\/\/doi.org\/10.1002\/jmv.24721","journal-title":"J Med Virol"},{"issue":"6","key":"11749_CR80","first-page":"722","volume":"181","author":"J Imanishi","year":"1987","unstructured":"Imanishi J, Ike H, Yamada A (1987) Inhibitory Effect of Interferons and Tumor-Necrosis Factor (Tnf) on the Syncytium Formation by Bovine Leukemia-Virus. Cr Soc Biol 181(6):722\u2013726","journal-title":"Cr Soc Biol"},{"issue":"6","key":"11749_CR81","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1006\/cyto.2001.0967","volume":"16","author":"H Sentsui","year":"2001","unstructured":"Sentsui H, Murakami K, Inoshima Y, Yokoyama T, Inumaru S (2001) Anti-viral effect of recombinant bovine interferon gamma on bovine leukaemia virus. Cytokine 16(6):227\u2013231. https:\/\/doi.org\/10.1006\/cyto.2001.0967","journal-title":"Cytokine"},{"issue":"1\u20132","key":"11749_CR82","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.vetimm.2004.04.016","volume":"101","author":"K Murakami","year":"2004","unstructured":"Murakami K, Sentsui H, Inoshima Y, Inumaru S (2004) Increase in \u03b3\u03b4 T cells in the blood of cattle persistently infected with Bovine Leukemia Virus following administration of recombinant bovine IFN-\u03b3. Vet Immunol Immunop 101(1\u20132):61\u201371. https:\/\/doi.org\/10.1016\/j.vetimm.2004.04.016","journal-title":"Vet Immunol Immunop"},{"issue":"9","key":"11749_CR83","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.14202\/vetworld.2024.2096-2103","volume":"17","author":"K Mukantayev","year":"2024","unstructured":"Mukantayev K, Tursunov K, Adish Z, Kanayev D, Tokhtarova L, Nurtleu M et al (2024) Cytotoxic T-lymphocyte antigen 4 and programmed cell death ligand 1 blockade increases the effectiveness of interleukin-15 immunotherapy in a bovine leukemia model. Veterinary World 17(9):2096\u20132103. https:\/\/doi.org\/10.14202\/vetworld.2024.2096-2103","journal-title":"Veterinary World"},{"issue":"3","key":"11749_CR84","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/QAI.0000000000000608","volume":"69","author":"M Abad-Fernandez","year":"2015","unstructured":"Abad-Fernandez M, Dronda F, Moreno A, Casado JL, Perez-Elias MJ, Quereda C et al (2015) Brief Report: Reduced Cell-Associated HTLV-2 DNA in Antiretroviral Treated HIV-1-HCV-Coinfected Patients Who Either Received Interferon-alpha\/Ribavirin-Based Hepatitis C Therapy or Had Spontaneous HCV RNA Clearance. J Acquir Immune Defic Syndr 69(3):286\u2013290. https:\/\/doi.org\/10.1097\/QAI.0000000000000608","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"11749_CR85","doi-asserted-by":"publisher","first-page":"149","DOI":"10.7888\/juoeh.12.149","volume":"12","author":"Y Koyama","year":"1990","unstructured":"Koyama Y, Tanaka Y, Oda S, Yamashita U, Eto S (1990) Antiviral and antiproliferative activities of recombinant human interferon alpha 2, beta and gamma on HTLV-I and ATL cells in vitro. J UOEH 12(2):149\u2013161. https:\/\/doi.org\/10.7888\/juoeh.12.149","journal-title":"J UOEH"},{"issue":"6","key":"11749_CR86","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/0192-0561(92)90152-b","volume":"14","author":"C D\u2019Onofrio","year":"1992","unstructured":"D\u2019Onofrio C, Franzese O, Puglianiello A, Peci E, Lanzilli G, Bonmassar E (1992) Antiviral activity of individual versus combined treatments with interferon alpha, beta and gamma on early infection with HTLV-I in vitro. Int J Immunopharmacol 14(6):1069\u20131079. https:\/\/doi.org\/10.1016\/0192-0561(92)90152-b","journal-title":"Int J Immunopharmacol"},{"issue":"2","key":"11749_CR87","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0192-0561(93)90088-g","volume":"15","author":"C D\u2019Onofrio","year":"1993","unstructured":"D\u2019Onofrio C, Franzese O, Ricci F, Bonmassar E (1993) Combined treatments with interferon (alpha,beta) plus PGA1 to control early infection with HTLV-I in primary cord blood-derived mononuclear cells. Int J Immunopharmacol 15(2):125\u2013136. https:\/\/doi.org\/10.1016\/0192-0561(93)90088-g","journal-title":"Int J Immunopharmacol"},{"issue":"8","key":"11749_CR88","first-page":"2849","volume":"96","author":"ME El-Sabban","year":"2000","unstructured":"El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F et al (2000) Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation. Blood 96(8):2849\u20132855","journal-title":"Blood"},{"issue":"11","key":"11749_CR89","doi-asserted-by":"publisher","first-page":"4576","DOI":"10.1182\/blood-2002-09-2986","volume":"101","author":"R Nasr","year":"2003","unstructured":"Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y et al (2003) Arsenic\/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 101(11):4576\u20134582. https:\/\/doi.org\/10.1182\/blood-2002-09-2986","journal-title":"Blood"},{"issue":"3","key":"11749_CR90","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/10428190400019966","volume":"46","author":"R Mahieux","year":"2005","unstructured":"Mahieux R, Hermine O (2005) In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-alpha. Leuk Lymphoma 46(3):347\u2013355. https:\/\/doi.org\/10.1080\/10428190400019966","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"11749_CR91","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1182\/blood-2006-04-015537","volume":"109","author":"M Brown","year":"2007","unstructured":"Brown M, Bellon M, Nicot C (2007) Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 109(4):1653\u20131659. https:\/\/doi.org\/10.1182\/blood-2006-04-015537","journal-title":"Blood"},{"issue":"4","key":"11749_CR92","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/sj.leu.2401742","volume":"14","author":"A Bazarbachi","year":"2000","unstructured":"Bazarbachi A, Nasr R, El-Sabban ME, Mahe A, Mahieux R, Gessain A et al (2000) Evidence against a direct cytotoxic effect of alpha interferon and zidovudine in HTLV-I associated adult T cell leukemia\/lymphoma. Leukemia 14(4):716\u2013721. https:\/\/doi.org\/10.1038\/sj.leu.2401742","journal-title":"Leukemia"},{"key":"11749_CR93","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1742-4690-10-52","volume":"10","author":"S Kinpara","year":"2013","unstructured":"Kinpara S, Kijiyama M, Takamori A, Hasegawa A, Sasada A, Masuda T et al (2013) Interferon-alpha (IFN-alpha) suppresses HTLV-1 gene expression and cell cycling, while IFN-alpha combined with zidovudine induces p53 signaling and apoptosis in HTLV-1-infected cells. Retrovirology 10:52. https:\/\/doi.org\/10.1186\/1742-4690-10-52","journal-title":"Retrovirology"},{"issue":"7","key":"11749_CR94","first-page":"1244","volume":"10","author":"A Broniscer","year":"1996","unstructured":"Broniscer A, Ribeiro RC, Srinivas RV, Behm FG, Head DR, Raimondi SC et al (1996) An adolescent with HTLV-I-associated adult T cell leukemia treated with interferon-alfa and zidovudine. Leukemia 10(7):1244\u20131248","journal-title":"Leukemia"},{"issue":"10","key":"11749_CR95","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1182\/blood-2005-01-0335","volume":"106","author":"A Mone","year":"2005","unstructured":"Mone A, Puhalla S, Whitman S, Baiocchi RA, Cruz J, Vukosavljevic T et al (2005) Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine\/IFN-alpha-refractory adult T-cell leukemia. Blood 106(10):3380\u20133382. https:\/\/doi.org\/10.1182\/blood-2005-01-0335","journal-title":"Blood"},{"issue":"2","key":"11749_CR96","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1080\/10428190601071717","volume":"48","author":"G Kchour","year":"2007","unstructured":"Kchour G, Makhoul NJ, Mahmoudi M, Kooshyar MM, Shirdel A, Rastin M et al (2007) Zidovudine and interferon-alpha treatment induces a high response rate and reduces HTLV-1 proviral load and VEGF plasma levels in patients with adult T-cell leukemia from North East Iran. Leuk Lymphoma 48(2):330\u2013336. https:\/\/doi.org\/10.1080\/10428190601071717","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"11749_CR97","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/bloodadvances.2016001370","volume":"1","author":"B Macchi","year":"2017","unstructured":"Macchi B, Balestrieri E, Frezza C, Grelli S, Valletta E, Marcais A et al (2017) Quantification of HTLV-1 reverse transcriptase activity in ATL patients treated with zidovudine and interferon-alpha. Blood Adv 1(12):748\u2013752. https:\/\/doi.org\/10.1182\/bloodadvances.2016001370","journal-title":"Blood Adv"},{"issue":"6","key":"11749_CR98","first-page":"594","volume":"30","author":"Y Kuroda","year":"1990","unstructured":"Kuroda Y, Takashima H, Endo C, Neshige R, Kakigi R (1990) [Treatment of HTLV-I-associated myelopathy with alpha-interferon and high-dose of gamma-globulin]. Rinsho Shinkeigaku 30(6):594\u2013598","journal-title":"Rinsho Shinkeigaku"},{"issue":"2","key":"11749_CR99","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/0022-510x(91)90256-7","volume":"106","author":"K Shibayama","year":"1991","unstructured":"Shibayama K, Nakamura T, Nagasato K, Shirabe S, Tsujihata M, Nagataki S (1991) Interferon-alpha treatment in HTLV-I-associated myelopathy. Studies of clinical and immunological aspects. J Neurol Sci 106(2):186\u2013192. https:\/\/doi.org\/10.1016\/0022-510x(91)90256-7","journal-title":"J Neurol Sci"},{"issue":"1","key":"11749_CR100","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/j.1600-0404.1992.tb08059.x","volume":"86","author":"Y Kuroda","year":"1992","unstructured":"Kuroda Y, Kurohara K, Fujiyama F, Takashima H, Endo C, Matsui M et al (1992) Systemic interferon-alpha in the treatment of HTLV-I-associated myelopathy. Acta Neurol Scand 86(1):82\u201386. https:\/\/doi.org\/10.1111\/j.1600-0404.1992.tb08059.x","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"11749_CR101","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1212\/wnl.46.4.1016","volume":"46","author":"S Izumo","year":"1996","unstructured":"Izumo S, Goto I, Itoyama Y, Okajima T, Watanabe S, Kuroda Y et al (1996) Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46(4):1016\u20131021. https:\/\/doi.org\/10.1212\/wnl.46.4.1016","journal-title":"Neurology"},{"issue":"2","key":"11749_CR102","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0022-510x(96)05319-1","volume":"147","author":"K Yamasaki","year":"1997","unstructured":"Yamasaki K, Kira J, Koyanagi Y, Kawano Y, Miyano-Kurosaki N, Nakamura M et al (1997) Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy\/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci 147(2):135\u2013144. https:\/\/doi.org\/10.1016\/s0022-510x(96)05319-1","journal-title":"J Neurol Sci"},{"issue":"2","key":"11749_CR103","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/s0022-510x(98)00330-x","volume":"162","author":"P Gazzola","year":"1999","unstructured":"Gazzola P, Cocito L, De Maria A, Gabutti G, Mancardi GL (1999) Successful 2-year therapy with systemic interferon-alpha for HTLV-I associated myelopathy. J Neurol Sci 162(2):205\u2013207. https:\/\/doi.org\/10.1016\/s0022-510x(98)00330-x","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"11749_CR104","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jneuroim.2012.05.004","volume":"250","author":"H Rafatpanah","year":"2012","unstructured":"Rafatpanah H, Rezaee A, Etemadi MM, Hosseini RF, Khorram B, Afsahr L et al (2012) The impact of interferon-alpha treatment on clinical and immunovirological aspects of HTLV-1-associated myelopathy in northeast of Iran. J Neuroimmunol 250(1\u20132):87\u201393. https:\/\/doi.org\/10.1016\/j.jneuroim.2012.05.004","journal-title":"J Neuroimmunol"},{"issue":"5","key":"11749_CR105","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1590\/s0036-46652014000500013","volume":"56","author":"GM Viana","year":"2014","unstructured":"Viana GM, Silva MA, Souza VL, Lopes NB, Silva DL, Nascimento Mdo D (2014) Interferon beta-1a treatment in HTLV-1-associated myelopathy\/tropical spastic paraparesis: a case report. Rev Inst Med Trop Sao Paulo 56(5):443\u2013445. https:\/\/doi.org\/10.1590\/s0036-46652014000500013","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"4","key":"11749_CR106","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s13311-015-0369-3","volume":"12","author":"R Boostani","year":"2015","unstructured":"Boostani R, Vakili R, Hosseiny SS, Shoeibi A, Fazeli B, Etemadi MM et al (2015) Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy\/Tropical Spastic Paraparesis. Neurotherapeutics 12(4):887\u2013895. https:\/\/doi.org\/10.1007\/s13311-015-0369-3","journal-title":"Neurotherapeutics"},{"issue":"1","key":"11749_CR107","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1086\/380101","volume":"189","author":"M Saito","year":"2004","unstructured":"Saito M, Nakagawa M, Kaseda S, Matsuzaki T, Jonosono M, Eiraku N et al (2004) Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy\/tropical spastic paraparesis. J Infect Dis 189(1):29\u201340. https:\/\/doi.org\/10.1086\/380101","journal-title":"J Infect Dis"},{"issue":"1\u20132","key":"11749_CR108","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jneuroim.2004.02.007","volume":"151","author":"J Feng","year":"2004","unstructured":"Feng J, Misu T, Fujihara K, Misawa N, Koyanagi Y, Shiga Y et al (2004) Th1\/Th2 balance and HTLV-I proviral load in HAM\/TSP patients treated with interferon-alpha. J Neuroimmunol 151(1\u20132):189\u2013194. https:\/\/doi.org\/10.1016\/j.jneuroim.2004.02.007","journal-title":"J Neuroimmunol"},{"issue":"1\u20132","key":"11749_CR109","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jns.2006.02.004","volume":"246","author":"M Saito","year":"2006","unstructured":"Saito M, Nose H, Usuku K, Sabouri AH, Matsuzaki T, Izumo S et al (2006) Flow cytometry evaluation of the T-cell receptor Vbeta repertoire among human T-cell lymphotropic virus type-1 (HTLV-1) infected individuals: effect of interferon alpha therapy in HTLV-1-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP). J Neurol Sci 246(1\u20132):37\u201343. https:\/\/doi.org\/10.1016\/j.jns.2006.02.004","journal-title":"J Neurol Sci"},{"issue":"1\u20132","key":"11749_CR110","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jneuroim.2004.10.011","volume":"159","author":"K Narikawa","year":"2005","unstructured":"Narikawa K, Fujihara K, Misu T, Feng J, Fujimori J, Nakashima I et al (2005) CSF-chemokines in HTLV-I-associated myelopathy: CXCL10 up-regulation and therapeutic effect of interferon-alpha. J Neuroimmunol 159(1\u20132):177\u2013182. https:\/\/doi.org\/10.1016\/j.jneuroim.2004.10.011","journal-title":"J Neuroimmunol"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-11749-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-11749-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:08:38Z","timestamp":1775038118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-11749-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":110,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11749"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-11749-3","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This is a review study. Research is not involving Human Participants and\/or Animals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval and Consent to Participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Human Ethics and Consent to Participate declarations: not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate"}}],"article-number":"571"}}